These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16322314)

  • 1. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
    Rudek MA; Zhao M; Smith NF; Robey RW; He P; Hallur G; Khan S; Hidalgo M; Jimeno A; Colevas AD; Messersmith WA; Wolff AC; Baker SD
    Clin Cancer Res; 2005 Dec; 11(23):8503-11. PubMed ID: 16322314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies.
    Rudek MA; Zhao M; He P; Zabelina Y; Jin R; Messersmith WA; Wolff AC; Baker SD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Dec; 828(1-2):41-54. PubMed ID: 16253576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
    Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
    Messersmith WA; Rudek MA; Baker SD; Zhao M; Collins C; Colevas AD; Donehower RC; Carducci MA; Wolff AC
    Eur J Cancer; 2007 Jan; 43(1):78-86. PubMed ID: 17084620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
    Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
    Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
    Wang C; Liu KX
    Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
    Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
    Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.
    Daali Y; Ancrenaz V; Bosilkovska M; Dayer P; Desmeules J
    Metabolism; 2011 Nov; 60(11):1584-9. PubMed ID: 21550074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV.
    Rudek MA; Zabelina Y; Zhao M; Wolff AC; Baker SD
    Biomed Chromatogr; 2004 Jun; 18(5):282-7. PubMed ID: 15236435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
    Kumar GN; Rodrigues AD; Buko AM; Denissen JF
    J Pharmacol Exp Ther; 1996 Apr; 277(1):423-31. PubMed ID: 8613951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine.
    Ye L; Tang L; Gong Y; Lv C; Zheng Z; Jiang Z; Liu Z
    Xenobiotica; 2011 Jan; 41(1):46-58. PubMed ID: 21105783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
    Li J; Zhao M; He P; Hidalgo M; Baker SD
    Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).
    Liu W; Liu H; Sun H; Dong D; Ma Z; Wang Y; Wu B
    Xenobiotica; 2014 May; 44(5):455-64. PubMed ID: 24191862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450.
    Koga N; Ohta C; Kato Y; Haraguchi K; Endo T; Ogawa K; Ohta H; Yano M
    Xenobiotica; 2011 Nov; 41(11):927-33. PubMed ID: 21726170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.